Dasatinib

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 39, Issue , 2014, Pages 205-237

  Korashy, Hesham M ^a   Rahman, A F M Motiur ^a   Kassem, Mohammed Gabr ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Analysis; Cytochrome P450; Dasatinib; Synthesis; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; DRUG METABOLITE;

ARTICLE; BLEEDING; CARBON NUCLEAR MAGNETIC RESONANCE; COLORIMETRY; CORONARY ARTERY DISEASE; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG NOMENCLATURE; DRUG SOLUBILITY; DRUG SYNTHESIS; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MELTING POINT; MOLECULAR WEIGHT; PARTITION COEFFICIENT; PLASMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROPHOTOMETRY; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION; ULTRAVIOLET SPECTROSCOPY;

ANALYSIS; CYTOCHROME P450; DASATINIB; SYNTHESIS; TYROSINE KINASE INHIBITOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; HUMANS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 84899675643     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800173-8.00004-0     Document Type: Chapter

References (81)

1. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000, 69:373-398.
2. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S., Cornelius L.A., Das J., Doweyko A.M., Fairchild C., Hunt J.T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G.L., Schmidt R.J., Tokarski J., Wen M.L., Wityak J., Borzilleri R.M. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47:6658-6661.
3. Ramirez P., DiPersio J.F. Therapy options in imatinib failures. Oncologist 2008, 13:424-434.
4. B.C. Chen, R. Droghini, J. Lajeunesse, J. D. DiMarco, M. Galella, R. Chindambaram, Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors, US patent 2006004067, 2006.
5. Chemical Structure name was obtained from ChemBioDraw, ChemBioDraw Ultra 12.0. software.
6. Das J., Chen P., Norris D., Padmanabha R., Lin J., Moquin R.V., Shen Z., Cook L.S., Doweyko A.M., Pitt S., Pang S., Shen D.R., Fang Q., de Fex H.F., McIntyre K.W., Shuster D.J., Gillooly K.M., Behnia K., Schieven G.L., Wityak J., Barrish J.C. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 2006, 49:6819-6832.
7. Spirin P.V., Baskaran D., Orlova N.N., Rulina A.V., Nikitenko N.A., Chernolovskaya E.L., Zenkova M.A., Vlassov V.V., Rubtsov P.M., Chumakov P.M., Stocking C., Prassolov V.S. Downregulation of activated leukemic oncogenes AML1-ETO and RUNX1(K83N) expression with RNA-interference. Mol. Biol. (Mosk.) 2010, 44:876-888.
8. Rulina A.V., Spirin P.V., Prassolov V.S. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition. Biochemistry (Mosc.) 2010, 75:1650-1666.
9. Drug bank accession number is DB01254. http://www.drugbank.ca.
10. Sweetman S. Martindale: The Complete Drug Reference 2009, 709. Pharmaceutical press, London. 36 ed.
11. The Merck Index, an Encyclopedia of Chemicals, Drugs and Biologicals 2006, vol. 14:2829. Merck & Co., Inc., Whitehouse Station, NJ, USA. M.J. O'Neil, P.E. Heckelman, C.B. Koch, K.J. Roman, C.M. Kenny, M.R. D'Arecca (Eds.).
12. Chemical Abstracts Service (CAS) registry no. 302962-49-8. http://www.cas.org.
13. Chemspider ID: 2323020. http://www.chemspider.com.
14. R. Yan, Yang, Hao, Hou, Wen, Xu, Yongxiang synthesis process of dasatinib and intermediate, WO/2011/095126 A (2011).
15. Imming P., Sinning C., Meye A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 2006, 5:821-834.
16. McIntyre J., Castanner J., Bayes M. Dasatinib. Drugs Fut. 2006, 31:291.
17. J. Das, R. Radmanabha, P. Chen, D.J. Norris, A.M.P. Doweyko, J.L. Barrish, J. Wityak, Cyclic protein tyrosine kinase inhibitors, US patent US6596746, 2003.
18. B.C. Chen, R. Zhao, B. Wang, Process for preparing 2-aminothiazole-5-carboxamides as kinase inhibitors, US patent US 2005176965, 2005.
19. J. Das, R. Radmanabha, P. Chen, D.J. Norris, A.M.P. Doweyko, J.L. Barrish, J. Wityak, Cyclic protein tyrosine kinase inhibitors, Chinese patent CN1348370A, 2002.
20. Peter G.M. Green's Protective Groups in Organic Synthesis 2007, JohnWiley & Sons, Inc., NJ, USA, pp. 16-366. Fourth ed.
21. J.C. Li, B.C. Chen, D. Smith, J.H. Sun, Process for preparing N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino]thiazole-5-carboxamide and related metabolites thereof, US patent WO 2007106879 A2, 2007.
22. Veach D.R., Namavari M., Pillarsetty N., Santos E.B., Beresten-Kochetkov T., Lambek C., Punzalan B.J., Antczak C., Smith-Jones P.M., Djaballah H., Clarkson B., Larson S.M. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J. Med. Chem. 2007, 50:5853-5857.
23. Awidi A., Salem I.I., Najib N., Mefleh R., Tarawneh B. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. Leuk. Res. 2010, 34:714-717.
24. Bouchet S., Chauzit E., Ducint D., Castaing N., Canal-Raffin M., Moore N., Titier K., Molimard M. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin. Chim. Acta 2011, 412:1060-1067.
25. Davies A., Hayes A.K., Knight K., Watmough S.J., Pirmohamed M., Clark R.E. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk. Res. 2010, 34:702-707.
26. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., Di Perri G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:1721-1726.
27. Klawitter J., Zhang Y.L., Anderson N., Serkova N.J., Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed. Chromatogr. 2009, 23:1251-1258.
28. Micova K., Friedecky D., Faber E., Polynkova A., Adam T. Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin. Chim. Acta 2010, 411:1957-1962.
29. Miura M., Takahashi N., Sawada K. High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. Biomed. Chromatogr. 2010, 24:789-793.
30. Miura M., Takahashi N., Sawada K. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J. Chromatogr. Sci. 2011, 49:412-415.
31. Oostendorp R.L., Beijnen J.H., Schellens J.H., Tellingen O. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomed. Chromatogr. 2007, 21:747-754.
32. Parise R.A., Egorin M.J., Christner S.M., Shah D.D., Zhou W., Beumer J.H. A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:1894-1900.
33. Pursche S., Ottmann O.G., Ehninger G., Schleyer E. High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852:208-216.
34. Roth O., Spreux-Varoquaux O., Bouchet S., Rousselot P., Castaigne S., Rigaudeau S., Raggueneau V., Therond P., Devillier P., Molimard M., Maneglier B. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin. Chim. Acta 2010, 411:140-146.
35. Titier K., Picard S., Ducint D., Teilhet E., Moore N., Berthaud P., Mahon F.X., Molimard M. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 2005, 27:634-640.
36. Yuki M., Yamakawa Y., Uchida T., Nambu T., Kawaguchi T., Hamada A., Saito H. High-performance liquid chromatographic assay for the determination of nilotinib in human plasma. Biol. Pharm. Bull. 2011, 34:1126-1128.
37. Kamath A.V., Wang J., Lee F.Y., Marathe P.H. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother. Pharmacol. 2008, 61:365-376.
38. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 2002, 1602:114-130.
39. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin. Ther. 2007, 29:2289-2308.
40. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J.D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O.G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354:2542-2551.
41. Weisberg E., Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
42. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982, 5:649-655.
43. D'Avolio A., Simiele M., De Francia S., Ariaudo A., Baietto L., Cusato J., Fava C., Saglio G., Di Carlo F., Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). J. Pharm. Biomed. Anal. 2010, 59:109-116.
44. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., Pasquini R., Clark R.E., Hochhaus A., Hughes T.P., Gallagher N., Hoenekopp A., Dong M., Haque A., Larson R.A., Kantarjian H.M. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362:2251-2259.
45. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., Apperley J., Cervantes F., Cortes J., Deininger M., Gratwohl A., Guilhot F., Horowitz M., Hughes T., Kantarjian H., Larson R., Niederwieser D., Silver R., Hehlmann R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
46. Singh N., Kumar L., Meena R., Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur. J. Clin. Pharmacol. 2009, 65:545-549.
47. Faber E., Friedecky D., Micova K., Divoka M., Katrincsakova B., Rozmanova S., Jarosova M., Indrak K., Adam T. Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response. Int. J. Hematol. 2010, 91:897-902.
48. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004, 22:935-942.
49. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., Mahon F.X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
50. Holdhoff M., Supko J.G., Gallia G.L., Hann C.L., Bonekamp D., Ye X., Cao B., Olivi A., Grossman S.A. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol. 2010, 97:241-245.
51. Roche S., McMahon G., Clynes M., O'Connor R. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:3982-3990.
52. Nambu T., Hamada A., Nakashima R., Yuki M., Kawaguchi T., Mitsuya H., Saito H. Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. Biol. Pharm. Bull. 2011, 34:114-119.
53. D'Antonio M., Pendino V., Sinha S., Ciccarelli F.D. Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic Acids Res. 2012, 40:D978-D983.
54. Furlong M.T., Agrawal S., Hawthorne D., Lago M., Unger S., Krueger L., Stouffer B. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. J. Pharm. Biomed. Anal. 2012, 58:130-135.
55. FDA, Guidance for Industry, Bioanalytical Method Validation, 2001.
56. Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:1982-1996.
57. Hsieh Y., Galviz G., Zhou Q., Duncan C. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid Commun. Mass Spectrom. 2009, 23:1364-1370.
58. Taylor P.J. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 2005, 38:328-334.
59. Chambers E., Wagrowski-Diehl D.M., Lu Z., Mazzeo J.R. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 852:22-34.
60. Luo F.R., Yang Z., Camuso A., Smykla R., McGlinchey K., Fager K., Flefleh C., Castaneda S., Inigo I., Kan D., Wen M.L., Kramer R., Blackwood-Chirchir A., Lee F.Y. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin. Cancer Res. 2006, 12:7180-7186.
61. Mhaske D.V., Dhaneshwar S.R. Stability indicating HPTLC and LC determination of dasatinib in pharmaceutical dosage form. Chromatographia 2007, 66:95-102.
62. Vadia N., Rajput S. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement. Eur. J. Pharm. Sci. 2012, 45:8-18.
63. Sankar D.G., Rajeswari A., Babu A.N., Krishna M.V. UV-spectrophotometric determination of dasatinib in pharmaceutical dosage forms. Asian J. Chem. 2009, 21:5777-5779.
64. Johnson F.M., Agrawal S., Burris H., Rosen L., Dhillon N., Hong D., Blackwood-Chirchir A., Luo F.R., Sy O., Kaul S., Chiappori A.A. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010, 116:1582-1591.
65. Eley T., Luo F.R., Agrawal S., Sanil A., Manning J., Li T., Blackwood-Chirchir A., Bertz R. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J. Clin. Pharmacol. 2009, 49:700-709.
66. Brave M., Goodman V., Kaminskas E., Farrell A., Timmer W., Pope S., Harapanhalli R., Saber H., Morse D., Bullock J., Men A., Noory C., Ramchandani R., Kenna L., Booth B., Gobburu J., Jiang X., Sridhara R., Justice R., Pazdur R. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 2008, 14:352-359.
67. Porkka K., Koskenvesa P., Lundan T., Rimpilainen J., Mustjoki S., Smykla R., Wild R., Luo R., Arnan M., Brethon B., Eccersley L., Hjorth-Hansen H., Hoglund M., Klamova H., Knutsen H., Parikh S., Raffoux E., Gruber F., Brito-Babapulle F., Dombret H., Duarte R.F., Elonen E., Paquette R., Zwaan C.M., Lee F.Y. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008, 112:1005-1012.
68. Wang L., Christopher L.J., Cui D., Li W., Iyer R., Humphreys W.G., Zhang D. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab. Dispos. 2008, 36:1828-1839.
69. Li X., He Y., Ruiz C.H., Koenig M., Cameron M.D., Vojkovsky T. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab. Dispos. 2009, 37:1242-1250.
70. Christopher L.J., Cui D., Wu C., Luo R., Manning J.A., Bonacorsi S.J., Lago M., Allentoff A., Lee F.Y., McCann B., Galbraith S., Reitberg D.P., He K., Barros A., Blackwood-Chirchir A., Humphreys W.G., Iyer R.A. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab. Dispos. 2008, 36:1357-1364.
71. Dai G., Pfister M., Blackwood-Chirchir A., Roy A. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. J. Clin. Pharmacol. 2008, 48:1254-1269.
72. Hiwase D.K., White D., Zrim S., Saunders V., Melo J.V., Hughes T.P. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 2010, 24:658-660.
73. Hiwase D.K., Saunders V., Hewett D., Frede A., Zrim S., Dang P., Eadie L., To L.B., Melo J., Kumar S., Hughes T.P., White D.L. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res. 2008, 14:3881-3888.
74. Christopher L.J., Cui D., Li W., Barros A., Arora V.K., Zhang H., Wang L., Zhang D., Manning J.A., He K., Fletcher A.M., Ogan M., Lago M., Bonacorsi S.J., Humphreys W.G., Iyer R.A. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys. Drug Metab. Dispos. 2008, 36:1341-1356.
75. Copland M., Hamilton A., Elrick L.J., Baird J.W., Allan E.K., Jordanides N., Barow M., Mountford J.C., Holyoake T.L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
76. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108:286-291.
77. O'Hare T., Eide C.A., Tyner J.W., Corbin A.S., Wong M.J., Buchanan S., Holme K., Jessen K.A., Tang C., Lewis H.A., Romero R.D., Burley S.K., Deininger M.W. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5507-5512.
78. Quintas-Cardama A., Cortes J.E., O'Brien S., Ravandi F., Borthakur G., Liu D., Bleickardt E., Chen T.T., Kantarjian H.M. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009, 115:2912-2921.
79. Hochhaus A. Management of Bcr-Abl-positive leukemias with dasatinib. Expert Rev. Anticancer Ther. 2007, 7:1529-1536.
80. Coluccia A.M., Cirulli T., Neri P., Mangieri D., Colanardi M.C., Gnoni A., Di Renzo N., Dammacco F., Tassone P., Ribatti D., Gambacorti-Passerini C., Vacca A. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008, 112:1346-1356.
81. Miller A.A., Pang H., Hodgson L., Ramnath N., Otterson G.A., Kelley M.J., Kratzke R.A., Vokes E.E. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J. Thorac. Oncol. 2010, 5:380-384.